Xi'an Oripharm Technology Co.,Ltd

“Dedicated to providing you with the best product solutions!”

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsActive Pharmaceutical IngredientTamoxifen Citrate Nolvadex Soltamox API CAS 10540-29-1 For Anti Breast Cancer

Tamoxifen Citrate Nolvadex Soltamox API CAS 10540-29-1 For Anti Breast Cancer

Tamoxifen Citrate Nolvadex Soltamox API CAS 10540-29-1 For Anti Breast Cancer

Product Details:

Place of Origin: China
Brand Name: ORIPHARM
Certification: KOSHER/ISO9001/SGS
Model Number: XALY

Payment & Shipping Terms:

Minimum Order Quantity: 10g
Packaging Details: Double food grade plastics inside; Environmental protection carton/barrel outside or Customized packages.
Delivery Time: 3-5 work days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: Negotiation
Contact Now
Detailed Product Description
Synonyms: Nolvadex ; Soltamox Formula: C26H29NO
Formula Weight: 371.515 G·mol−1 CAS: 10540-29-1
Color: White Crystalline Powder Assay: 99% Min

Tamoxifen Nolvadex Soltamox API for Anti Breast Cancer CAS 10540-29-1​
 

Product NameTamoxifen
CAS No.10540-29-1
SynonymsNolvadex; Soltamox
Molecular FormulaC26H29NO
Molecular Weight371.515 g·mol−1
StructureTamoxifen Citrate Nolvadex Soltamox API CAS 10540-29-1 For Anti Breast Cancer
Purity99% Min
Usage

Anti Breast Cancer

CharacterWhite crystalline powder
GradePharmaceutical Grade
StandardUSP,CP
Delivery methodEMS, DHL, TNT, FedEx
 
Description :
Tamoxifen, also known by the brand name Nolvadex, is among the a lot more frequently prescribed medicines to stop breast cancer recurrence, and when employed appropriately, may well lower the threat of recurrence (of breast cancer coming back) by roughly 50 %. The drug may perhaps also be made use of to reduce the chance that a lady will develop breast cancer in the first spot, or to slow the growth of metastatic breast cancer. Tamoxifen operates by binding to estrogen receptors on breast cells in order that estrogen cannot bind and stimulate development. Study concerning the prospective negative effects, how drug interactions might happen, and how tamoxifen differs from aromatase inhibitors.
Applications:
Tamoxifen was approved in 1998 and has considering that been found powerful in treating breast cancer for millions of persons. It can be still considered a great option when you are premenopausal or are postmenopausal and cannot take an aromatase inhibitor.
When made use of following major treatment (eg. surgery) it might minimize your risk of breast cancer recurrence by half if your tumor was estrogen receptor positive. It might also lessen your threat of building yet another cancer inside the very same breast or possibly a new cancer in your other breast by as much as 50 percent. This decreased danger holds true both for all those who've a high or low threat.
It might be valuable to comprehend that tamoxifen continues to possess rewards in decreasing the risk of recurrence even following you quit taking the drug.
Also to its effects on lowering breast cancer risk or recurrence, tamoxifen has other positive aspects as well. In contrast to its anti-estrogen effects on breast tissue, tamoxifen has estrogen-like effects on bone. As a result tamoxifen (also as Evista) may aid slow or cease bone loss. (In contrast, aromatase inhibitors frequently cause bone loss). Tamoxifen could also reduce cholesterol levels, specifically LDL cholesterol.

 

Tamoxifen Nolvadex Soltamox API for Anti Breast Cancer CAS 10540-29-1​

 

COA:

ProductTamoxifenCAS No.10540-29-1
Quantity1KGDate Of Manu2019-01-11
Test standardIn-house quality standardExpiry date2021-01-10
ItemsSpecificationsResults
AppearanceWhite crystalline powderWhite crystalline powder
Assay≥99%99.43%
Loss on Drying≤1.0%0.4%
Conclusion: The product meets In-house specifications.
 
 
 


More information please contact us NOW!
 

Contact Details
Xi'an Oripharm Technology Co.,Ltd

Contact Person: forrest

Send your inquiry directly to us (0 / 3000)